Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Centanafadine Extended-release Capsules in Pediatric ADHD
NCT04081363Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of centanafadine in attention deficit hyperactivity disorder (ADHD) (2 cohorts), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Maximum Plasma Concentration at 12 hours, Time to Maximum Plasma Concentration at 12 hours and 1 more. Started Oct 2019; status: completed.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04081363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081363.